Journal of Clinical Pediatrics >
Clinical diagnosis and treatment of Kawasaki disease-associated macrophage activation syndrome in children
Received date: 2023-04-13
Online published: 2023-07-05
Kawasaki disease is a systemic vasculitis. Macrophage activation syndrome is a severe complication of pediatric rheumatic immune diseases, which is characterized by cytokine storms and has a rapid progression and high mortality rate. Early identification of Kawasaki disease-associated macrophage activation syndrome is difficult, and its main features include persistent fever, splenomegaly, elevated ferritin levels, and decreased platelets. At present, there is no uniform diagnostic criteria for this disease, which mainly refers to the diagnostic criteria of systemic juvenile idiopathic arthritis with macrophage activation syndrome and primary hemophagocytic lymphohistiocytosis. Meanwhile, this disease should be distinguished from Kawasaki disease shock syndrome and childhood multisystem inflammatory syndrome. Glucocorticoids are the main treatment drugs, and patients with poor response can use traditional immunosuppressants such as cyclosporine. Biologic agents and targeted drugs have broad prospects.
Key words： Kawasaki disease; macrophage activation syndrome; cytokine storm; child
Sheng HAO , Min HUANG . Clinical diagnosis and treatment of Kawasaki disease-associated macrophage activation syndrome in children[J]. Journal of Clinical Pediatrics, 2023 , 41(7) : 486 -491 . DOI: 10.12372/jcp.2022.23e0317
| [1] | Gorelik M, Chung SA, Ardalan K, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease[J]. Arthritis Care Res (Hoboken), 2022, 74(4): 538-548. |
| [2] | Saadoun D, Vautier M, Cacoub P. Medium- and large-vessel vasculitis[J]. Circulation, 2021, 143(3): 267-282. |
| [3] | Tirelli F, Marrani E, Giani T, et al. One year in review: Kawasaki disease[J]. Curr Opin Rheumatol, 2020, 32(1): 15‐20. |
| [4] | McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era[J]. Nat Rev Rheumatol, 2021, 17(3): 145-157. |
| [5] | Wang W, Gong F, Zhu W, et al. Macrophage activation syndrome in Kawasaki disease: more common than we thought?[J]. Semin Arthritis Rheum, 2015, 44(4): 405-410. |
| [6] | Crayne C, Cron RQ. Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg[J]. Eur J Rheumatol, 2020, 7(Suppl 1): 13-20. |
| [7] | 郝胜. 儿童风湿性疾病相关巨噬细胞活化综合征诊断与治疗专家共识之五——川崎病篇[J]. 中国实用儿科杂志, 2020, 35(11): 23-27. |
| [8] | Pilania RK, Jindal AK, Johnson N, et al. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India[J]. Rheumatology (Oxford), 2021, 60(7): 3413-3419. |
| [9] | Filipovich AH, Chandrakasan S. Pathogenesis of hemophagocytic lymphohistiocytosis[J]. Hematol Oncol Clin North Am, 2015, 29(5): 895-902. |
| [10] | Crayne CB, Albeituni S, Nichols KE, et al. The immu-nology of macrophage activation syndrome[J]. Front Immunol, 2019, 10: 119. |
| [11] | Zhang M, Behrens EM, Atkinson TP, et al. Genetic defects in cytolysis in macrophage activation syndrome[J]. Curr Rheumatol Rep, 2014, 16(9): 439. |
| [12] | Kaufman KM, Linghu B, Szustakowski JD, et al. Whole-exome sequencing reveals overlap between macrophage activation syndrome in systemic juvenile idiopathic arthritis and familial hemophagocytic lymphohistiocytosis[J]. Arthritis Rheumatol, 2014, 66(12): 3486-3495. |
| [13] | Brisse E, Wouters C, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities[J]. Br J Haematol, 2016, 174(2): 203-217. |
| [14] | Carter SJ, Tattersall R, Ramanan AV, et al. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment[J]. Rheu-matology (Oxford), 2019, 58(1): 5-17. |
| [15] | Jinkawa A, Shimizu M, Nishida K, et al. Cytokine profile of macrophage activation syndrome associated with Kawasaki disease[J]. Cytokine, 2019, 119: 52-56. |
| [16] | Han SB, Lee SY. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches[J]. World J Pediatr, 2020, 16(6): 566-574. |
| [17] | 周利兵, 吕海涛. 川崎病并发巨噬细胞活化综合征的研究进展[J]. 临床儿科杂志, 2018, 36(10): 74-78. |
| [18] | Jin P, Luo Y, Liu X, et al. Kawasaki disease complicated with macrophage activation syndrome: case reports and literature review[J]. Front Pediatr, 2019, 7: 423. |
| [19] | Kang H, Kwon YH, Yoo E, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease[J]. Blood Res, 2013, 48(4): 254-257. |
| [20] | García-Pavón S, Yamazaki-Nakashimada MA, Báez M, et al. Kawasaki disease complicated with macrophage activation syndrome: a systematic review[J]. J Pediatr Hematol Oncol, 2017, 39(6): 445-451. |
| [21] | Zhang HY, Xiao M, Zhou D, et al. Platelet and ferritin as early predictive factors for the development of macrophage activation syndrome in children with Kawasaki disease: a retrospective case-control study[J]. Front Pediatr, 2023, 11: 1088525. |
| [22] | 何胜男, 唐雪梅, 张宇, 等. 川崎病相关巨噬细胞活化综合征临床分析及诊断标准初探[J]. 中华实用儿科临床杂志, 2018, 33(9): 679-683. |
| [23] | 何涛, 钟家蓉, 张静. 川崎病并发巨噬细胞活化综合征9例病例报告并文献复习[J]. 中国循证儿科杂志, 2018, 13(6): 421-426. |
| [24] | Nofech-Mozes Y, Garty BZ. Thrombocytopenia in Kawasaki disease: a risk factor for the development of coronary artery aneurysms[J]. Pediatr Hematol Oncol, 2003, 20(8): 597-601. |
| [25] | Bode SF, Lehmberg K, Maul-Pavicic A, et al. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis[J]. Arthritis Res Ther, 2012, 14(3): 213. |
| [26] | Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy[J]. Nat Rev Rheumatol, 2016, 12(5): 259‐268. |
| [27] | Sharma C, Ganigara M, Galeotti C, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison[J]. Nat Rev Rheumatol, 2021, 17(12): 731-748. |
| [28] | Otar Yener G, Pa? K?saarslan A, Ulu K, et al. Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative study[J]. Rheumatol Int, 2022, 42(5): 879-889. |
| [29] | Bukulmez H. Current understanding of multisystem inflammatory syndrome (MIS-C) following COVID-19 and its distinction from Kawasaki disease[J]. Curr Rheumatol Rep, 2021, 23(8): 58. |
| [30] | Lopez-Leon S, Wegman-Ostrosky T, Ayuzo Del Valle NC, et al. Long-COVID in children and adolescents: a systematic review and meta-analyses[J]. Sci Rep, 2022, 12(1): 9950. |
| [31] | Tong T, Yao X, Lin Z, et al. Similarities and differences between MIS-C and KD: a systematic review and meta-analysis[J]. Pediatr Rheumatol Online J, 2022, 20(1): 112. |
| [32] | Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features[J]. Arthritis Care Res (Hoboken), 2011, 63(4): 465‐482. |
| [33] | Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis[J]. N Engl J Med, 2020, 382(19): 1811-1822. |
| [34] | De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome[J]. Ann Rheum Dis, 2023, 82(6): 857-865. |
| [35] | 郝胜, 黄文彦, 曾华松. 小分子靶向JAK抑制剂在儿童风湿免疫性疾病中的应用[J]. 中国实用儿科杂志, 2021, 36(11): 853-857. |
| [36] | 赵坚, 谢利剑, 肖婷婷, 等. 联合体外膜肺治疗川崎病休克综合征1例报告并文献复习[J]. 临床儿科杂志, 2019, 37(9): 708-711. |
| [37] | Kim HK, Kim HG, Cho SJ, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease[J]. Pediatr Hematol Oncol, 2011, 28(3): 230-236. |
| [38] | Choi JE, Kwak Y, Huh JW, et al. Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide[J]. Korean J Pediatr, 2018, 61(5): 167-173. |
| [39] | Latino GA, Manlhiot C, Yeung RS, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease[J]. J Pediatr Hematol Oncol, 2010, 32(7): 527-531. |
| [40] | Zou LX, Zhu Y, Sun L, et al. Clinical and laboratory features, treatment, and outcomes of macrophage activation syndrome in 80 children: a multi-center study in China[J]. World J Pediatr, 2020, 16(1): 89-98. |
/
| 〈 |
|
〉 |
